Bioequivalence

BE is an important evaluation indicator in the drug development evaluation process, which is used to compare the similarity of bioavailability between a new drug and an original drug in vivo. A variety of factors need to be considered comprehensively in actual operation due to national and regional regulatory requirements, the direction of drug research and development are different. Meanwhile, in the design and protocol development of the trial, the specific drug characteristics and patient types need to be fully evaluated and considered to ensure the accuracy and reliability of the test results. In recent years, Quarkmed has more than 100 projects of BE service and abundant experience, and has won the trust and recognition of partners.

Clinical project experience and department involved (including but not limited to):

• Infection Department

• Psychiatry Department

• Cardiovascular Department

• Neurology Department

• Dermatology Department

• Oncology Department

• Gynecology Department

• Urology Surgery

• Endocrine Department

• Hematology Department

• Pediatric Department

• Gastroenterology Department

• Respiratory Medicine Department

• Orthopedics Department